loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Icatibant reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Menu

    Icatibant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 591,988Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Firazyr

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Firazyr

    Icatibant

    arrow
    Formnext Forum
    Not Confirmed

    Brand Name : Firazyr

    Japan
    arrow
    Formnext Forum
    Not Confirmed

    Takeda

    Icatibant

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2019 Revenue in Millions : 272

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Firazyr

    Icatibant

    arrow
    Formnext Forum
    Not Confirmed

    Brand Name : Firazyr

    Japan
    arrow
    Formnext Forum
    Not Confirmed

    Takeda

    Icatibant

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 286

    2019 Revenue in Millions : 277

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Firazyr

    Icatibant

    arrow
    Formnext Forum
    Not Confirmed

    Brand Name : Firazyr

    Japan
    arrow
    Formnext Forum
    Not Confirmed

    Takeda

    Icatibant

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 238

    2020 Revenue in Millions : 274

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Firazyr

    Icatibant

    arrow
    Formnext Forum
    Not Confirmed

    Brand Name : Firazyr

    Japan
    arrow
    Formnext Forum
    Not Confirmed

    Takeda

    Icatibant

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 193

    2021 Revenue in Millions : 238

    Growth (%) : -19

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Firazyr

    Icatibant

    arrow
    Formnext Forum
    Not Confirmed

    Brand Name : Firazyr

    Japan
    arrow
    Formnext Forum
    Not Confirmed

    Takeda

    Icatibant

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 150

    2022 Revenue in Millions : 193

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Firazyr

    Icatibant

    arrow
    Formnext Forum
    Not Confirmed

    Brand Name : Firazyr

    Ireland
    arrow
    Formnext Forum
    Not Confirmed

    Shire

    Icatibant

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2016 Revenue in Millions : 579

    2015 Revenue in Millions : 445

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Firazyr

    Icatibant

    arrow
    Formnext Forum
    Not Confirmed

    Brand Name : Firazyr

    Ireland
    arrow
    Formnext Forum
    Not Confirmed

    Shire

    Icatibant

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2017 Revenue in Millions : 663

    2016 Revenue in Millions : 579

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF